FDA approves mirikizumab, a promising induction and maintenance therapy for ulcerative colitis
The U.S. Food and Drug Administration (FDA) approved mirikizumab, on October 26, 2023, a highly effective new treatment for ulcerative colitis (UC), offering a new option to patients battling this chronic and debilitating ...
Oct 30, 2023
0
0